Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
7.95
-0.12 (-1.49%)
At close: Feb 18, 2025, 4:00 PM
7.87
-0.08 (-1.00%)
After-hours: Feb 18, 2025, 5:54 PM EST
Zevra Therapeutics Employees
As of December 31, 2023, Zevra Therapeutics had 69 total employees, including 65 full-time and 4 part-time employees. The number of employees increased by 33 or 91.67% compared to the previous year.
Employees
69
Change (1Y)
33
Growth (1Y)
91.67%
Revenue / Employee
$354,913
Profits / Employee
-$1,299,478
Market Cap
424.34M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
ZVRA News
- 19 days ago - Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™ - GlobeNewsWire
- 20 days ago - Zevra Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market - CNBC
- 2 months ago - Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024 - GlobeNewsWire
- 2 months ago - Zevra Therapeutics Announces Organizational Changes - GlobeNewsWire
- 3 months ago - Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C - GlobeNewsWire
- 3 months ago - Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting - GlobeNewsWire